AHA News: These Diets Helped Women With Diabetes Cut Heart Attack, Stroke Risk

THURSDAY, Sept. 19, 2019 (American Heart Association News) -- Eating patterns similar to the Mediterranean diet and the blood pressure-lowering DASH may help older women with Type 2 diabetes ward off heart attacks, strokes and related problems, new...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

In conclusion, it remains unclear if brain-specific regional and temporal changes occur in the expression of the different APP variants during AD progression. Since APP is also found in blood cells, assessing the changes in APP mRNA expression in peripheral blood cells from AD patients has been considering an alternative. However, again the quantification of APP mRNA in peripheral blood cells has generated controversial results. Brain APP protein has been analyzed in only a few studies, probably as it is difficult to interpret the complex pattern of APP variants and fragments. We previously characterized the soluabl...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Metabolic diseases and diabetes represent an increasing global challenge for human health care. As associated with a strongly elevated risk of developing atherosclerosis, kidney failure and death from myocardial infarction or stroke, the treatment of diabetes requires a more effective approach than lowering blood glucose levels. This review summarizes the evidence for the cardioprotective benefits induced by antidiabetic agents, including sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), along with sometimes conversely discussed effects of dipeptidyl peptidase-4 inhib...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionsThis analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost ‐effective use of UK healthcare resources and may provide long‐term health benefits to patients.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
AbstractPurpose of ReviewPatients with established cardiovascular disease are at high risk for recurrent myocardial infarction, stroke, and cardiovascular death. The termresidual risk refers to this risk that persists, even after optimal treatment. Considerable progress has been made to understand the biological basis of residual risk and to devise therapies that can safely and effectively reduce risk. The presence of ongoing subclinical vascular inflammation is known to be a marker of elevated residual risk, and reductions in measures of vascular inflammation predict improved outcome in these patients.Recent FindingsRecen...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
CONCLUSION: These data indicate that SGLT-2is is more beneficial to MACE and all-cause mortality in T2DM patients than DPP-4is. PMID: 32888896 [PubMed - as supplied by publisher]
Source: Primary Care - Category: Primary Care Authors: Tags: Prim Care Diabetes Source Type: research
In this study, we sought to elucidate the role of VRK-1 in regulation of adult life span in C. elegans. We found that overexpression of VRK-1::GFP (green fluorescent protein), which was detected in the nuclei of cells in multiple somatic tissues, including the intestine, increased life span. Conversely, genetic inhibition of vrk-1 decreased life span. We further showed that vrk-1 was essential for the increased life span of mitochondrial respiratory mutants. We demonstrated that VRK-1 was responsible for increasing the level of active and phosphorylated form of AMPK, thus promoting longevity. A Fisetin Variant, C...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractBackgroundPatients with diabetes who had a recent myocardial infarction (MI) are at high risk of cardiovascular events. Therefore, risk assessment is important for treatment and shared decisions. We used data from EXAMINE trial to investigate whether a multi-proteomic approach would provide specific proteomic signatures and also improve the prognostic capacity for determining the risk of cardiovascular death, MI, stroke, heart failure [HF], all-cause death, and combinations of these outcomes.Methods93 circulating proteins (92 from the Olink ® CVDII plus troponin) were assessed in 5131 patients. Cox, competing r...
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
This article reviews CVOTs completed to date for the class of long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs; liraglutide, exenatide extended-release, albiglutide, dulaglutide, semaglutide injectable, semaglutide oral) and implications for clinical management of T2DM. All CVOTs have confirmed long-acting GLP-1RAs to be noninferior to (not worse than) placebo with regard to first occurrence of a primary outcome of three-point major adverse cardiovascular events (MACE; composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). Further, a number of the studies demonstrated a ...
Source: Journal of the American Academy of Physician Assistants - Category: Primary Care Tags: Long-Acting GLP-1 Receptor Agonists Source Type: research
More News: Cardiology | Diabetes | Diabetes Type 2 | Diets | Endocrinology | General Medicine | Heart | Heart Attack | Nutrition | Stroke | Women